Compare Novavax Inc (NVAX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Veritone Inc — how do they compare? Novavax Inc trades at $9.85 (market cap $1.62B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Novavax Inc is far larger — about 18.9× Veritone Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VERI | |
|---|---|---|
Market Cap | $1.62B | $85.83M |
Sector | Health | Technology |
52-Week High | $11.19 | $8.39 |
52-Week Low | $6.22 | $0.79 |
Enterprise Value | $1.20B | $121.22M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $111.73 million in 2025, with revenue of $92.19 million, and has missed earnings expectations in recent quarters. Recent news includes a securities class action investigation and partnerships to expand AI solutions.
Outlook remains challenged by persistent losses and legal overhangs, though cost reduction efforts and AI partnerships offer potential growth. Investment risks include high cash burn, negative margins, and shareholder litigation. Analyst sentiment is mixed with a slight buy bias, but fundamental weakness limits near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
